{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:22:12Z","timestamp":1788391332207,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.vaccine.2019.03.015","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:08:43Z","timestamp":1553018923000},"page":"2200-2207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15\u202fyears old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study"],"prefix":"10.1016","volume":"37","author":[{"given":"Juan J.","family":"Picazo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Ruiz-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Casado-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagrario","family":"Negreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Baquero-Artigao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hern\u00e1ndez-Sampelayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Otheo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del","family":"Amo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.03.015_b0005","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper\u20132012","volume":"87","author":"(WHO) WHO","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.03.015_b0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O'Brien","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.03.015_b0015","doi-asserted-by":"crossref","unstructured":"Klugman KP, Black S, Dagan R, Malley R, Whitney CG. Vaccines. In: Stanley A. Plotkin WAOaPAO, W.B. Saunders, editor. Vaccines. Sixth edition ed. London2013. p. 504-41.","DOI":"10.1016\/B978-1-4557-0090-5.00032-X"},{"key":"10.1016\/j.vaccine.2019.03.015_b0020","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1378\/chest.105.5.1487","article-title":"Severe community-acquired pneumonia","volume":"105","author":"Moine","year":"1994","journal-title":"CHEST"},{"key":"10.1016\/j.vaccine.2019.03.015_b0025","doi-asserted-by":"crossref","unstructured":"Whitney CG, Farley Mm Fau - Hadler J, Hadler J Fau - Harrison LH, Harrison Lh Fau - Bennett NM, Bennett Nm Fau - Lynfield R, Lynfield R Fau - Reingold A, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. 2003.","DOI":"10.1056\/NEJMoa022823"},{"key":"10.1016\/j.vaccine.2019.03.015_b0030","doi-asserted-by":"crossref","unstructured":"Kyaw MH, Lynfield R Fau - Schaffner W, Schaffner W Fau - Craig AS, Craig As Fau - Hadler J, Hadler J Fau - Reingold A, Reingold A Fau - Thomas AR, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. 2006.","DOI":"10.1056\/NEJMoa051642"},{"key":"10.1016\/j.vaccine.2019.03.015_b0035","doi-asserted-by":"crossref","unstructured":"Beall BW, Gertz Re Fau - Hulkower RL, Hulkower Rl Fau - Whitney CG, Whitney Cg Fau - Moore MR, Moore Mr Fau - Brueggemann AB, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. 2011","DOI":"10.1093\/infdis\/jir052"},{"key":"10.1016\/j.vaccine.2019.03.015_b0040","doi-asserted-by":"crossref","unstructured":"Hicks LA, Harrison Lh Fau - Flannery B, Flannery B Fau - Hadler JL, Hadler Jl Fau - Schaffner W, Schaffner W Fau - Craig AS, Craig As Fau - Jackson D, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. 2007.","DOI":"10.1086\/521626"},{"key":"10.1016\/j.vaccine.2019.03.015_b0045","doi-asserted-by":"crossref","unstructured":"Pai R, Moore Mr Fau - Pilishvili T, Pilishvili T Fau - Gertz RE, Gertz Re Fau - Whitney CG, Whitney Cg Fau - Beall B, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. 2005.","DOI":"10.1086\/498043"},{"key":"10.1016\/j.vaccine.2019.03.015_b0050","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/JCM.01454-08","article-title":"Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007","volume":"47","author":"Fenoll","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.03.015_b0055","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.285.13.1729","article-title":"Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995\u20131998: opportunities for prevention in the conjugate vaccine era","volume":"285","author":"Robinson","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.03.015_b0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/528996","article-title":"Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005","volume":"197","author":"Moore","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.015_b0065","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/j.vaccine.2010.04.020","article-title":"Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development","volume":"28","author":"Reinert","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.015_b0070","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.vaccine.2010.12.114","article-title":"Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007\u20132009) laboratory-based surveillance in Madrid","volume":"29","author":"Picazo","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.015_b0075","first-page":"394","article-title":"Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older","volume":"61","author":"(CDC) CfDCaP","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.03.015_b0080","doi-asserted-by":"crossref","first-page":"e0172222","DOI":"10.1371\/journal.pone.0172222","article-title":"Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007\u20132015","volume":"12","author":"Picazo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.03.015_b0085","unstructured":"(CLSI) CaLSI. Methods for dilution antimicrobial susceptibility tests for bacteria thar grow aerobically. Clinical and Laboratory Standards. 7th ed, approved standard M7-A& ed. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2006."},{"key":"10.1016\/j.vaccine.2019.03.015_b0090","unstructured":"(CLSI) CaLI. Performance Standards for Antimicrobial Susceptibility Testing. Approved Standard M100-S24. Clinical Laboratory Standards. Wayne, PA: Clinical Laboratory Institute (CLSI); 2014"},{"key":"10.1016\/j.vaccine.2019.03.015_b0095","unstructured":"(INE) INdE."},{"key":"10.1016\/j.vaccine.2019.03.015_b0100","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1086\/324358","article-title":"Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection","volume":"34","author":"Michelow","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.015_b0105","unstructured":"Worldometers. European countries by population (2018). Worldometers; 2018."},{"key":"10.1016\/j.vaccine.2019.03.015_b0110","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1038\/s41598-017-08717-0","article-title":"Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology","volume":"7","author":"Kwambana-Adams","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.03.015_b0115","doi-asserted-by":"crossref","first-page":"20750","DOI":"10.2807\/1560-7917.ES2014.19.12.20750","article-title":"Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012","volume":"19","author":"Aguiar","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.03.015_b0120","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.vaccine.2013.03.049","article-title":"Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010\u20132020","volume":"31","author":"Link-Gelles","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.015_b0125","doi-asserted-by":"crossref","first-page":"e73704","DOI":"10.1371\/journal.pone.0073704","article-title":"The majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5","volume":"8","author":"Horacio","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.03.015_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/CVI.00317-10","article-title":"Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar","volume":"18","author":"Picazo","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.03.015_b0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2042018816638223","article-title":"Review of vancomycin-induced renal toxicity: an update","volume":"7","author":"Bamgbola","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"802\u201312","key":"10.1016\/j.vaccine.2019.03.015_b0140","first-page":"e1","article-title":"Pneumococcal vaccination in Europe: schedule adherence","volume":"36","author":"Gervaix","year":"2014","journal-title":"Clin Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:22:40Z","timestamp":1663114960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19303263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0264410X19303263"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15\u202fyears old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}